Intragraft interleukin 2 mRNA expression during acute cellular rejection and left ventricular total wall thickness after heart transplantation


Objective: To assess whether diastolic graft function is influenced by intragraft interleukin 2 (IL-2) messenger RNA (mRNA) expression in rejecting cardiac allografts.

Design: 16 recipients of cardiac allografts were monitored during the first three months after transplantation. The presence of IL-2 mRNA in endomyocardial biopsies (n = 123) was measured by reverse transcriptase polymerase chain reaction. To determine heart function, concurrent M mode and two dimensional Doppler echocardiograms were analysed.

Results: Histological signs of acute rejection (International Society for Heart and Lung Transplantation (ISHLT) rejection grade > 2) were strongly associated with IL-2 mRNA expression (IL-2 mRNA was present in 12 of 20 endomyocardial biopsies (60%) with acute rejection and in 24 of 103 endomyocardial biopsies (23%) without acute rejection, p = 0.002). No significant relation was found between either histology or IL-2 mRNA expression alone and the studied echocardiographic parameters. However, stratification of the echocardiographic data into those of patients with and those without acute rejection showed that during acute rejection IL-2 mRNA expression was significantly associated with increased left ventricular total wall thickness (mean change in total wall thickness was +0.22 cm in patients with IL-2 mRNA expression versus −0.18 cm in patients without IL-2 mRNA expression, p = 0.048).

Conclusions: An increase in left ventricular total wall thickness precedes IL-2 positive acute rejection after heart transplantation. Thus, cardiac allograft rejection accompanied by intragraft IL-2 mRNA expression may be indicative of more severe rejection episodes.

Reversible diastolic dysfunction of cardiac allografts in the first postoperative months has been reported to correlate with reduced long term survival. This diastolic dysfunction can be the result of acute rejection, a major complication shortly after transplantation. However, not all histologically proven acute rejection episodes result in changes of diastolic function parameters. The underlying mechanism of the difference between acute rejection episodes with and those without impaired heart function is unknown but may involve the local or systemic release of cytokines.

Acute cellular rejection is morphologically characterised by the presence of a mononuclear cell infiltrate and signs of myocyte damage on endomyocardial biopsy (EMB). The combination of infiltrated immune competent cells with interstitial and perivascular oedema, vascular leakage of fibrin, and in the more severe cases diffuse myocyte necrosis can result in stiffness of the myocardium. Consequently, the acute rejection process may change left ventricular wall dimensions and left ventricular filling parameters, reflecting the loss of diastolic heart function. Previously reported echocardiographic changes related to acute cellular rejection include increased left ventricular total wall thickness, increased peak early mitral flow velocity (E), decreased deceleration time, and shortened isovolumetric relaxation period. Alternatively, during vascular (humoral) rejection, cells of the microvasculature instead of myocytes may be the target of tissue injury, which has been associated with increased left ventricular mass and depressed myocyte function.

In addition to cell infiltration and tissue damage, local production of cytokines (low molecular weight regulatory proteins) during rejection may also influence myocardial function. One of the crucial cytokines in the modulation of the alloimmune response is interleukin (IL) 2, which enhances the proliferation and differentiation of specific T lymphocytes directed against the allograft. In non-transplant settings, IL-2 has been shown to cause dysfunction of the heart both in experimental and in clinical studies. A dose dependent negative inotropic effect of IL-2 was observed in isolated hamster papillary muscle preparations. Moreover, intravenous administration of IL-2 in patients with cancer causes cardiovascular side effects including decreased ejection fraction, decreased blood pressure, increased heart rate, and fluid retention. Therefore, we speculate that after transplantation the local presence of IL-2 may be related to allograft dysfunction by reflecting the severity of the immune response against the allograft and by its direct negative inotropic effect on the myocardium. To determine whether local IL-2 expression during histological rejection indeed affects diastolic graft function, we monitored serially sampled EMB for the presence of IL-2 messenger RNA (mRNA) expression and for histological signs of acute rejection during the first three months after heart transplantation. These findings were analysed in relation to echocardiographic changes in wall dimensions and diastolic flow parameters.

Abbreviations: AR+, in the presence of acute rejection; AR−, in the absence of acute rejection; cDNA, complementary DNA; E, peak early mitral flow velocity; EMB, endomyocardial biopsy; IL, interleukin; ISHLT, International Society for Heart and Lung Transplantation; mRNA, messenger RNA; PCR, polymerase chain reaction.
Table 1  Demographics of the studied patients and the numbers of endomyocardial biopsies (EMB) positive for acute rejection (AR+) and interleukin 2 (IL-2) messenger RNA (mRNA) expression (IL-2+)

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Primary disease</th>
<th>EMB</th>
<th>AR+</th>
<th>EMB</th>
<th>IL-2+ EMB</th>
<th>AR+/IL-2+</th>
<th>AR-/IL-2+</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20</td>
<td>F</td>
<td>CMP</td>
<td>8</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>52</td>
<td>M</td>
<td>IHD</td>
<td>9</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>60</td>
<td>M</td>
<td>IHD</td>
<td>Excluded from the study due to poor echocardiographic quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>48</td>
<td>M</td>
<td>IHD</td>
<td>9</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>58</td>
<td>M</td>
<td>CMP</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>51</td>
<td>M</td>
<td>CMP</td>
<td>8</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>56</td>
<td>F</td>
<td>CMP</td>
<td>7</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>58</td>
<td>M</td>
<td>IHD</td>
<td>9</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>9</td>
<td>53</td>
<td>F</td>
<td>CMP</td>
<td>8</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>50</td>
<td>M</td>
<td>IHD</td>
<td>7</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>16</td>
<td>F</td>
<td>CMP</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>54</td>
<td>M</td>
<td>IHD</td>
<td>8</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>13</td>
<td>43</td>
<td>M</td>
<td>CMP</td>
<td>8</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>14</td>
<td>55</td>
<td>M</td>
<td>IHD</td>
<td>9</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>15</td>
<td>58</td>
<td>M</td>
<td>IHD</td>
<td>9</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>16</td>
<td>52</td>
<td>M</td>
<td>IHD</td>
<td>10</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>123</td>
<td>20</td>
<td>36</td>
<td>12</td>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CMP, cardiomyopathy; F, female; IHD, ischaemic heart disease; M, male.

METHODS

Patients

We studied 16 consecutive heart transplant recipients who were operated upon between November 1997 and October 1998. Table 1 summarises the demographical data of these patients. Maintenance immunosuppressive therapy consisted of ciclosporin A and low dose steroids. Serial EMB and echocardiograms during the first three months after transplantation were studied. Surveillance biopsies during this period were taken weekly during the first six weeks and biweekly during the following eight weeks. During routine biopsies two additional samples were harvested for cytokine studies after informed consent of the patients. One patient has been excluded from analysis because of the poor quality of serial echocardiograms, leaving 15 patients in the study group. In total, 123 biopsies with concurrent echocardiograms (on average eight time points per patient) were available for analysis. Acute rejection was diagnosed by histological assessment of myocardial biopsies and graded according to the guidelines of the International Society for Heart and Lung Transplantation (ISHLT). Patients with ISHLT rejection grade > 2 were considered to have an acute rejection (AR+) and received additional immunosuppressive treatment.

Echocardiography

Echocardiographic examination was completed within four hours of biopsy sampling using a Hewlett Packard Sonos 500 or 5300 ultrasonograph (Hewlett Packard, Palo Alto, California, USA) with a 3.75 MHz transducer. All recordings were made and analysed by a single investigator without knowledge of the results of EMB. M mode recordings for measurement of left ventricular wall dimensions were obtained from the parasternal long axis view in combination with an ECG, phonocardiogram, and respiratory tracing. For two dimensional Doppler echocardiography the transducer was positioned at the cardiac apex for a standard apical four chamber view. Mitral flow velocities were recorded within the valve orifice near the leaflet tips with the sample volume placed parallel to the ventricular inflow tract.

Offline, M mode, and two dimensional Doppler echocardiograms were analysed using a software program developed in our laboratory with a hand held digitiser connected to a digitising tablet (Summa Sketch Plus, Summagraphics, Seymour, Connecticut, USA) interfaced with a personal computer. For M mode echocardiogram analysis, mean of five consecutive end expiratory beats were calculated. M mode echocardiograms were analysed for end diastolic posterior left ventricular wall thickness and end diastolic interventricular septum thickness. Left ventricular total wall thickness was calculated by adding end diastolic posterior wall thickness and end diastolic interventricular septum thickness. Two dimensional Doppler echocardiograms were analysed for the following diastolic function parameters: E, peak atrial mitral flow velocity (A), E/A ratio, deceleration time of E, and isovolumetric relaxation period. For Doppler echocardiogram analysis, means of 10 consecutive end expiratory beats were calculated. Beats that were distorted by the recipient atrial contraction were not analysed with respect to deceleration time. The transmitral filling pattern was classified as “summation filling” when only one peak occurred in diastole after the P wave of the succeeding beat. In such recordings, E and A waves could not be recognised and consequently the parameters E, A, E/A ratio, and deceleration time were not measured.

IL-2 mRNA detection

Reverse transcriptase polymerase chain reaction (PCR) was used for detection of IL-2 mRNA expression. Therefore, total RNA was extracted from snap frozen EMB, and subsequently complementary DNA (cDNA) was synthesised with random primers as described previously in detail. Aliquots of cDNA (representing 1/20 EMB) were directly used for PCR amplification using sequence specific primers for IL-2 (sense: 5’-ATG TAG AGG ATG CAA CTC CTG TCT T-3’; antisense: 5’-GTC AGT GGT GAG ATG ATG CTG TTA C-3’). Sample cDNA (5 µl) was added to a 95 µl PCR mixture containing 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM each of deoxy-ATP, deoxy-CTP, deoxy-TPP, and deoxy-GTP 2 U Taq polymerase (Applied Biosystems, Norwalk, Connecticut, USA) and overlaid with 100 µl mineral oil (Sigma, St Louis, Missouri, USA) before PCR in a DNA thermal cycler model 480 (Applied Biosystems) under the following conditions. After a 5 minute 94°C denaturation step, samples underwent 40 cycles of denaturation for 1 minute at 94°C, 2 minutes’ annealing at 60°C, and 3 minutes’ extension at 72°C. The last cycle was extended to 7 minutes at 72°C.

Positive control samples were produced by mRNA extraction and cDNA synthesis from 107 random human spleen cells stimulated with 1% phytohaemagglutinin M (Difco, Detroit, Michigan, USA) for 24 hours at 37°C. Negative control samples consisted of ethidium bromide treated RNA or H2O as a no template reaction. In all samples, constitutively expressed glyceraldehyde 3-phosphate dehydrogenase mRNA was amplified in a separate PCR (3-phosphate dehydrogenase

www.heartjnl.com
The presence of IL-2 mRNA on an agarose gel was visually assessed as present (IL-2 positive) or not present (IL-2 negative) and confirmed by Southern blot hybridisation. Therefore, products on the agarose gel were transferred to a Hybond-N membrane (Amersham, Buckinghamshire, UK) by electroblotting and subsequently hybridised with a 32P labelled specific probe for IL-2 (5'-GTT GAA GTG CGG AGT CAA CG-3', antisense: 5'-CAA AGT TGT CAT GGA TGA CC-3') to confirm successful mRNA extraction and cDNA transcription. EMB that were negative for 3-phosphate dehydrogenase mRNA expression were excluded from further analysis.

Statistical analysis

Differences in mean echocardiographic parameters between EMB with and those without either histologically proven acute rejection or IL-2 mRNA expression were analysed by Student’s t test. Associations between IL-2 mRNA expression and acute rejection, as well as changes in wall dimension between the first measurement and the first acute rejection biopsy with or without IL-2 mRNA expression, were calculated by Fisher’s exact test in a cross table. Associations with p < 0.05 were considered significant.

RESULTS

Acute rejection

In 4 of 16 patients no histological signs of acute rejection were observed during the first three months after transplantation. These non-rejectors served as the control group. One of the rejectors (patients with at least one AR+ biopsy) was excluded from analysis because of poor echocardiographic quality. Overall, 20 of 123 EMB were positive for acute rejection (16%). Table 1 shows the total number of AR+ biopsies with acute rejection during follow up of the patients.

IL-2 mRNA expression in relation to rejection

Serial measurements of IL-2 mRNA expression showed that every patient in the rejector group and in the non-rejector group had at least one IL-2 positive EMB during the first three months after transplantation. Overall, IL-2 mRNA expression was detected in 36 of 123 EMB (29%). Table 1 summarises the number of IL-2 positive EMB in the presence (AR+) or absence of acute rejection (AR−) during follow up. IL-2 mRNA expression was strongly associated with histological signs of acute rejection requiring treatment. IL-2 mRNA was present in 12 of 20 EMB (60%) with histological signs of acute rejection and in 24 of 103 EMB (23%) without these histological characteristics (p = 0.002, Fisher’s exact test; table 2).

Diastolic function in relation to rejection and IL-2 mRNA expression

A large individual variation was observed in the echocardiographic measurements. No differences in the echocardiographic variables were observed at the group level between AR+ and AR− biopsies (table 3), between biopsies with or without IL-2 mRNA expression (table 3), or between the sub-divided AR+ and AR− samples in biopsies with or without IL-2 mRNA expression (table 4).

In the search for changes over time, differences in the echocardiographic parameters were calculated between the first postoperative measurement and the time of the first acute rejection or IL-2 mRNA expression. In this way, each patient served as his or her own control. Because the first echocardiographic measurement was used as the baseline, patients with acute rejection or IL-2 mRNA expression at the time of their first measurement (n = 2 and n = 4, respectively) were excluded from this specific analysis. Neither histological signs of acute rejection nor IL-2 mRNA expression alone was associated with individual changes over time in any of the studied echocardiographic parameters. However, by relating intragraft IL-2 positivity to echocardiographic changes over time after stratifying the data into AR+ and AR− time points, we found that IL-2 mRNA expression during the first acute rejection was significantly associated with increased left ventricular total wall thickness between the first postoperative measurement and the first acute rejection episode (fig 1). In five of six patients with IL-2 mRNA expression during their first acute rejection, increased total wall thickness had preceded that rejection episode (mean (SD) change between the first postoperative measurement and the measurement during the first acute rejection episode was +0.22 (0.12) cm). In all patients without IL-2 mRNA expression during their first acute rejection, total wall thickness decreased (mean (SD) –0.18 (0.12) cm; p = 0.048, Fisher’s exact test; fig 1). In all non-rejecting control patients, total wall thickness decreased during their first IL-2 positive EMB with respect to the first postoperative measurement (mean (SD) –0.30 (0.31) cm). The only patient in whom total wall thickness had decreased preceding an IL-2 positive acute rejection episode had an exceptionally high total wall thickness of 2.68 cm during the first postoperative measurement, which may be attributable to the known history of hypertension of the donor. During the IL-2 positive rejection episode, the total wall thickness of this patient decreased to 2.32 cm, which is still relatively high.
ventricular filling (low A and increased E/A ratio).

- Passive filling phase in association with a rapid increase of left ventricular filling pressure during the isovolumetric relaxation period; rapid filling of the left ventricle during the diastolic active filling period.

- Increased left ventricular mass in the absence of clinical signs of acute rejection may also be the result of vascular (humoral) injury, in which the cells of the microvasculature are targeted for injury early in the alloimmune response. However, because vascular rejection was not determined routinely in EMB, we were unable to evaluate the contribution of vascular rejection (alone or in combination with cellular rejection) to left ventricular thickening in our patients.

**IL-2 mRNA expression in relation to rejection**

- IL-2 is a key regulator of cellular immunity by its autocrine stimulation of T cell maturation, differentiation, proliferation, and apoptosis.

- In agreement with our previous results, we found a strong relation between local IL-2 mRNA expression in EMB and histological signs of acute rejection.

- However, IL-2 mRNA is not always present during acute rejection and, inversely, acute rejection is not always diagnosed during the presence of IL-2 mRNA. Several factors may explain this discrepancy. Firstly, as a result of sampling errors the diagnosis of acute rejection may be false negative. Secondly, because of the redundancy of the cytokine network, lymphocyte proliferation can be stimulated by alternative T cell growth factors (such as IL-15) during inhibition of IL-2 mRNA expression by immunosuppressive therapy.

**Diastolic function in relation to IL-2 mRNA expression**

- New onset left ventricular dysfunction after heart transplantation may be caused by the presence and cytotoxic effects of infiltrating immune cells, but may also depend on the production of cytokines (such as IL-2) by these infiltrating cells.

**DISCUSSION**

**Diastolic function in relation to rejection**

Numerous investigators have explored the clinical use of echocardiography to replace invasive EMB sampling for the diagnosis of acute rejection. During acute rejection, high left atrial pressures combined with increased myocardial stiffness can lead to a number of echocardiographic changes such as early opening of the mitral valve (short isovolumetric relaxation period); rapid filling of the left ventricle during the passive filling phase in association with a rapid increase of left ventricular pressure (high E and decreased deceleration time); and subsequent small contribution of atrial contraction to left ventricular filling (low A and increased E/A ratio). Although some authors described an association between acute rejection and echocardiographic variables at the group level, the considerable overlap between individual patients still limits replacement of EMB as the benchmark for diagnosis of acute rejection after heart transplantation.

In the present study, no direct association was found at the group level between the studied echocardiographic parameters and histological evidence of acute rejection alone. This is in agreement with earlier findings and can be explained by the influence of numerous factors. Besides the risk of false negative biopsies and the effect of the immune response, left ventricular filling properties and heart morphology can be affected by loading conditions, hypertension, oedema resulting from ischaemia/reperfusion injury, and treatment with diuretics or vasodilators. Moreover, it has been described that treatment with cyclosporin, in comparison with previous treatment strategies without calcineurin blockers, results in less pronounced morphological and functional changes during acute rejection with loss of sensitivity of echocardiographic parameters. Furthermore, diastolic function parameters improve in the early postoperative period, reflecting recovery from the operative insult, which may conceal acute changes caused by the rejection process. Increased left ventricular mass in the absence of histological signs of acute rejection may also be the result of vascular (humoral) injury, in which the cells of the microvasculature are targeted for injury early in the alloimmune response. However, because vascular rejection was not determined routinely in EMB, we were unable to evaluate the contribution of vascular rejection (alone or in combination with cellular rejection) to left ventricular thickening in our patients.

**Table 4 Echocardiographic parameters at the time of EMB with (AR+) and without (AR−) acute rejection and with (IL-2+) and without (IL-2−) IL-2 mRNA expression**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>AR+/IL-2−</th>
<th>AR-/IL-2+</th>
<th>p Value</th>
<th>AR+/IL-2−</th>
<th>AR-/IL-2+</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TWT (cm)</td>
<td>2.16 (0.30)</td>
<td>2.05 (0.30)</td>
<td>0.13</td>
<td>2.02 (0.14)</td>
<td>2.19 (0.31)</td>
<td>0.12</td>
</tr>
<tr>
<td>E (m/s)</td>
<td>0.82 (0.19)</td>
<td>0.84 (0.28)</td>
<td>0.66</td>
<td>0.71 (0.28)</td>
<td>0.87 (0.17)</td>
<td>0.13</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>2.22 (0.73)</td>
<td>2.14 (0.63)</td>
<td>0.68</td>
<td>1.70 (0.54)</td>
<td>2.18 (0.86)</td>
<td>0.25</td>
</tr>
<tr>
<td>DET (ms)</td>
<td>161.5 (31.3)</td>
<td>175.2 (30.4)</td>
<td>0.11</td>
<td>143.3 (6.5)</td>
<td>156.1 (37.3)</td>
<td>0.32</td>
</tr>
<tr>
<td>IRP (ms)</td>
<td>64.69 (19.50)</td>
<td>65.22 (21.60)</td>
<td>0.92</td>
<td>64.64 (26.16)</td>
<td>74.17 (12.07)</td>
<td>0.37</td>
</tr>
</tbody>
</table>

Data are mean (SD).

A, peak atrial mitral flow velocity; DET, deceleration time of peak early mitral flow velocity; E, peak early mitral flow velocity; IRP, isovolumetric relaxation period; TWT, left ventricular total wall thickness.

**Figure 1** Change in left ventricular total wall thickness (TWT) (%) from the first postoperative measurement to the first acute rejection (AR) in patients without (n = 3) and with (n = 6) interleukin 2 (IL-2) messenger RNA expression during that first acute rejection (left) and to the first IL-2 positive biopsy in control patients with no signs of acute rejection episode (n = 4, right); p = 0.048, Fisher’s exact test.

**Figure 2** TWT change before first AR (%) in patients with (AR+) and without (AR−) IL-2+ or IL-2− mRNA expression in EMB.

**Table 5** Presence of IL-2 mRNA expression in EMB at the time of EMB and at the time of EMB with positive IL-2+ mRNA expression and without IL-2− mRNA expression.

<table>
<thead>
<tr>
<th>Presence of IL-2 mRNA</th>
<th>AR+/IL-2−</th>
<th>AR-/IL-2+</th>
<th>p Value</th>
<th>AR+/IL-2−</th>
<th>AR-/IL-2+</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of AR</td>
<td>3</td>
<td>6</td>
<td>0.11</td>
<td>4</td>
<td>2</td>
<td>0.12</td>
</tr>
<tr>
<td>Presence of IL-2+</td>
<td>2</td>
<td>4</td>
<td>0.12</td>
<td>3</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Presence of AR+ IL-2+</td>
<td>2</td>
<td>4</td>
<td>0.12</td>
<td>3</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

**Figure 3** TWT change before first AR (%) in patients with (AR+) and without (AR−) IL-2+ or IL-2− mRNA expression in EMB.

**Table 6** Diastolic function parameters at the time of EMB with (AR+) and without (AR−) acute rejection and with (IL-2+) and without (IL-2−) IL-2 mRNA expression.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>AR+/IL-2−</th>
<th>AR-/IL-2+</th>
<th>p Value</th>
<th>AR+/IL-2−</th>
<th>AR-/IL-2+</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TWT (cm)</td>
<td>2.16 (0.30)</td>
<td>2.05 (0.30)</td>
<td>0.13</td>
<td>2.02 (0.14)</td>
<td>2.19 (0.31)</td>
<td>0.12</td>
</tr>
<tr>
<td>E (m/s)</td>
<td>0.82 (0.19)</td>
<td>0.84 (0.28)</td>
<td>0.66</td>
<td>0.71 (0.28)</td>
<td>0.87 (0.17)</td>
<td>0.13</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>2.22 (0.73)</td>
<td>2.14 (0.63)</td>
<td>0.68</td>
<td>1.70 (0.54)</td>
<td>2.18 (0.86)</td>
<td>0.25</td>
</tr>
<tr>
<td>DET (ms)</td>
<td>161.5 (31.3)</td>
<td>175.2 (30.4)</td>
<td>0.11</td>
<td>143.3 (6.5)</td>
<td>156.1 (37.3)</td>
<td>0.32</td>
</tr>
<tr>
<td>IRP (ms)</td>
<td>64.69 (19.50)</td>
<td>65.22 (21.60)</td>
<td>0.92</td>
<td>64.64 (26.16)</td>
<td>74.17 (12.07)</td>
<td>0.37</td>
</tr>
</tbody>
</table>

Data are mean (SD).

A, peak atrial mitral flow velocity; DET, deceleration time of peak early mitral flow velocity; E, peak early mitral flow velocity; IRP, isovolumetric relaxation period; TWT, left ventricular total wall thickness.
ventricular total wall thickness. This increase was not seen in patients with IL-2 positive AR—EMB or in patients with IL-2 negative acute rejections. We speculate that the IL-2 expression during acute rejection in our patient group may reflect the severity of the inflammation process during acute rejection. We did not observe a similar association with the measured functional parameters (E, A, deceleration time, and isovolumetric relaxation period), probably because of the large influence of loading conditions and blood pressure on these parameters. Our previous finding that IL-2 mRNA expression during the first acute rejection is associated with early development of graft vascular disease supports the hypothesis that IL-2 positive acute rejection episodes are more serious than IL-2 negative acute rejections. 5 Because vascular leakage is a known side effect of IL-2 immunotherapy, it is likely that the wall thickness increase after IL-2 positive rejection episodes is the result of oedema. 6 IL-2 may lead to oedema by stimulating the production of inducible nitric oxide synthase, leading to overproduction of nitric oxide, which has been reported to cause capillary damage followed by fluid leakage. 5

In summary, our results show a significant increase of left ventricular total wall thickness before IL-2 positive acute rejection. Whether vascular rejection plays a part in this process remains to be determined. We conclude that rejection accompanied by intragraft IL-2 mRNA expression has a greater influence on heart morphology and therefore may be indicative of more severe rejection.

 AUTHORS’ AFFILIATIONS

*H A de Groot-Kruiseman, C C Baan, W M Mol, W Weimar, Department of Internal Medicine, University Hospital Rotterdam, Rotterdam, Netherlands
H G Niesters, Diagnostic Institute of Molecular Biology, University Hospital Rotterdam, Rotterdam, Netherlands
A P Maaß, Department of Thoracic Surgery, University Hospital Rotterdam, Rotterdam, Netherlands
E M Hagman, A H Pols, Department of Cardiology, University Hospital Rotterdam, Rotterdam, Netherlands
P E Zondervan, Department of Pathology, University Hospital Rotterdam, Rotterdam, Netherlands

*Also the Department of Cardiology

REFERENCES


www.heartjnl.com
Intragraft interleukin 2 mRNA expression during acute cellular rejection and left ventricular total wall thickness after heart transplantation


Heart 2002 87: 363-367
doi: 10.1136/heart.87.4.363

Updated information and services can be found at:
http://heart.bmj.com/content/87/4/363

These include:

References
This article cites 27 articles, 5 of which you can access for free at:
http://heart.bmj.com/content/87/4/363#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Clinical diagnostic tests (4779)
Echocardiography (2127)
Interventional cardiology (2933)
Hypertension (3006)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/